Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. (Q44615027)
Jump to navigation
Jump to search
scientific article published in October 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. |
scientific article published in October 2003 |
Statements
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling (English)
Qing-Bai She
David Solit
Andrea Basso
Mark M Moasser
1 October 2003